This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow [Online Appendix]
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schachter, H. M.
Right arrow Articles by Moher, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schachter, H. M.
Right arrow Articles by Moher, D.
Related Collections
Right arrow Drugs: psychiatry
Right arrow Other evidence-based medicine
Right arrow Child and adolescent psychiatry
CMAJ • November 27, 2001; 165 (11)
© 2001 Canadian Medical Association or its licensors

Research
Recherche

How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis

Howard M. Schachter*, Ba' Pham*, Jim King{dagger}{ddagger}, Stephanie Langford and David Moher*{ddagger}

From *the Thomas C. Chalmers Centre for Systematic Reviews, Children's Hospital of Eastern Ontario (CHEO) Research Institute; {dagger}the Department of Pediatrics, CHEO; and {ddagger}the Department of Pediatrics, University of Ottawa, Ottawa, Ont.

Correspondence to: Dr. Howard M. Schachter, Thomas C. Chalmers Centre for Systematic Reviews, Children's Hospital of Eastern Ontario Research Institute, 401 Smyth Rd., Ottawa ON K1H 8L1; fax 613 738-4869; hschacht{at}uottawa.ca

Background: Numerous small clinical trials have been carried out to study the behaviourally defined efficacy and safety of short-acting methylphenidate compared with placebo for attention-deficit disorder (ADD) in individuals aged 18 years and less. However, no meta-analyses that carefully examined these questions have been done. We reviewed the behavioural evidence from all the randomized controlled trials that compared methylphenidate and placebo, and completed a meta-analysis.

Methods: We searched several electronic sources for articles published between 1981 and 1999: MEDLINE, EMBASE, PsychINFO, ERIC, CINAHL, HEALTHSTAR, Biological Abstracts, Current Contents and Dissertation Abstracts. The Cochrane Library Trials Registry and Current Controlled Trials were also consulted. A study was considered eligible for inclusion if it entailed the following: a placebo- controlled randomized trial that involved short-acting methylphenidate and participants aged 18 years or less at the start of the trial who had received any primary diagnosis of ADD that was made in a systematic and reproducible way.

Results: We included 62 randomized trials that involved a total of 2897 participants with a primary diagnosis of ADD (e.g., with or without hyperactivity). The median age of trial participants was 8.7 years, and the median "percent male" composition of trials was 88.1%. Most studies used a crossover design. Using the scores from 2 separate indices, this collection of trials exhibited low quality. Interventions lasted, on average, 3 weeks, with no trial lasting longer than 28 weeks. Each primary outcome (hyperactivity index) demonstrated a significant effect of methylphenidate (effect size reported by teacher 0.78, 95% confidence interval [CI] 0.64–0.91; effect size reported by parent 0.54, 95% CI 0.40–0.67). However, these apparent beneficial effects are tempered by a strong indication of publication bias and the lack of robustness of the findings, especially those involving core ADD features. Methylphenidate also has an adverse event profile that requires consideration. For example, clinicians only need to treat 4 children to identify an episode of decreased appetite.

Interpretation: Short-acting methylphenidate has a statistically significant clinical effect in the short-term treatment of individuals with a diagnosis of ADD aged 18 years and less. However, the extension of this placebo-controlled effect beyond 4 weeks of treatment has not been demonstrated. Exact knowledge of the extent and definition of the short-term behavioural usefulness of methylphenidate is questioned.




This article has been cited by other articles:


Home page
 BMJHome page
A. Chatterjee
Is it acceptable for people to take methylphenidate to enhance performance? No
BMJ, June 18, 2009; 338(jun18_2): b1956 - b1956.
[Full Text]

Home page
 JAMAHome page
W. Weber, A. Vander Stoep, R. L. McCarty, N. S. Weiss, J. Biederman, and J. McClellan
Hypericum perforatum (St John's Wort) for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: A Randomized Controlled Trial
JAMA, June 11, 2008; 299(22): 2633 - 2641.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
S. B. Wigal, T. E. Wilens, M. Wolraich, and M. Lerner
Hematologic and Blood Biochemistry Monitoring During Methylphenidate Treatment in Children With Attention-Deficit/Hyperactivity Disorder: 2-Year, Open-Label Study Results
Pediatrics, July 1, 2007; 120(1): e120 - e128.
[Abstract] [Full Text] [PDF]

Home page
 Arch Gen PsychiatryHome page
G. Polanczyk, C. Zeni, J. P. Genro, A. P. Guimaraes, T. Roman, M. H. Hutz, and L. A. Rohde
Association of the Adrenergic {alpha}2A Receptor Gene With Methylphenidate Improvement of Inattentive Symptoms in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder
Arch Gen Psychiatry, February 1, 2007; 64(2): 218 - 224.
[Abstract] [Full Text] [PDF]

Home page
 J PsychopharmacolHome page
D. J. Nutt, K. Fone, P. Asherson, D. Bramble, P. Hill, K. Matthews, K. A. Morris, P. Santosh, E. Sonuga-Barke, E. Taylor, et al.
Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology
J Psychopharmacol, January 1, 2007; 21(1): 10 - 41.
[Abstract] [PDF]

Home page
 Arch Pediatr Adolesc MedHome page
T. E. Wilens, K. McBurnett, O. Bukstein, J. McGough, L. Greenhill, M. Lerner, M. A. Stein, C. K. Conners, J. Duby, J. Newcorn, et al.
Multisite Controlled Study of OROS Methylphenidate in the Treatment of Adolescents With Attention-Deficit/Hyperactivity Disorder
Arch Pediatr Adolesc Med, January 1, 2006; 160(1): 82 - 90.
[Abstract] [Full Text] [PDF]

Home page
 J Atten DisordHome page
B. N. Bohnstedt, W. G. Kronenberger, D. W. Dunn, A. L. Giauque, E. A. Wood, M. E. Rembusch, and D. Lafata
Investigator Ratings of ADHD Symptoms During a Randomized, Placebo-Controlled Trial of Atomoxetine: A Comparison of Parents and Teachers as Informants
J Atten Disord, May 1, 2005; 8(4): 153 - 159.
[Abstract] [PDF]

Home page
 PediatricsHome page
A. J. Richardson and P. Montgomery
The Oxford-Durham Study: A Randomized, Controlled Trial of Dietary Supplementation With Fatty Acids in Children With Developmental Coordination Disorder
Pediatrics, May 1, 2005; 115(5): 1360 - 1366.
[Abstract] [Full Text] [PDF]

Home page
 Med Decis MakingHome page
K. Secnik, L. S. Matza, S. Cottrell, E. Edgell, D. Tilden, and S. Mannix
Health State Utilities for Childhood Attention-Deficit/Hyperactivity Disorder Based on Parent Preferences in the United Kingdom
Med Decis Making, January 1, 2005; 25(1): 56 - 70.
[Abstract] [PDF]

Home page
 PediatricsHome page
P. Panei, R. Arcieri, S. Vella, M. Bonati, N. Martini, and A. Zuddas
Italian Attention-Deficit/Hyperactivity Disorder Registry
Pediatrics, August 1, 2004; 114(2): 514 - 514.
[Full Text] [PDF]

Home page
 Adv. Psychiatr. Treat.Home page
M. Zwi and A. York
Attention-deficit hyperactivity disorder in adults: validity unknown
Adv. Psychiatr. Treat., July 1, 2004; 10(4): 248 - 256.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
D. K. Kelsey, C. R. Sumner, C. D. Casat, D. L. Coury, H. Quintana, K. E. Saylor, V. K. Sutton, J. Gonzales, S. K. Malcolm, K. J. Schuh, et al.
Once-Daily Atomoxetine Treatment for Children With Attention-Deficit/Hyperactivity Disorder, Including an Assessment of Evening and Morning Behavior: A Double-Blind, Placebo-Controlled Trial
Pediatrics, July 1, 2004; 114(1): e1 - e8.
[Abstract] [Full Text] [PDF]

Home page
 International Journal of ToxicologyHome page
S. K. Teo, D. I. Stirling, S. D. Thomas, M. G. Evans, and V. D. Khetani
A 90-Day Oral Gavage Toxicity Study of d-Methylphenidate and d, I-Methylphenidate in Beagle Dogs
International Journal of Toxicology, May 1, 2003; 22(3): 215 - 226.
[Abstract] [PDF]

Home page
 Am. J. PsychiatryHome page
D. Michelson, A. J. Allen, J. Busner, C. Casat, D. Dunn, C. Kratochvil, J. Newcorn, F. R. Sallee, R. B. Sangal, K. Saylor, et al.
Once-Daily Atomoxetine Treatment for Children and Adolescents With Attention Deficit Hyperactivity Disorder: A Randomized, Placebo-Controlled Study
Am J Psychiatry, November 1, 2002; 159(11): 1896 - 1901.
[Abstract] [Full Text] [PDF]

Home page
 Evid. Based Ment. HealthHome page
D. F Connor
Review: short acting methylphenidate has short term efficacy in children and adolescents with attention deficit disorder
Evid. Based Ment. Health, May 1, 2002; 5(2): 50 - 50.
[Full Text] [PDF]

Home page
 CMAJHome page
L. Jerome
Treatment of attention- deficit hyperactivity disorder
Can. Med. Assoc. J., May 1, 2002; 166(10): 1251 - 1252.
[Full Text] [PDF]

Home page
 CMAJHome page
B. Vitiello
Methylphenidate in the treatment of children with attention-deficit hyperactivity disorder
Can. Med. Assoc. J., November 1, 2001; 165(11): 1505 - 1506.
[Full Text] [PDF]